Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

In BRAF(V600mut) metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers. Based on phase III clinical trial data, several studies have previo...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancers (Basel)
Prif Awduron: Louveau, Baptiste, Jouenne, Fanelie, Reger de Moura, Coralie, Sadoux, Aurelie, Baroudjian, Barouyr, Delyon, Julie, Herms, Florian, De Masson, Adele, Da Meda, Laetitia, Battistella, Maxime, Dumaz, Nicolas, Lebbe, Celeste, Mourah, Samia
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6721518/
https://ncbi.nlm.nih.gov/pubmed/31426590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11081203
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg